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Abstract
The unfolded protein response is a critical system by which the cell handles excess misfolded protein in the secretory
pathway. The role of the system in modulating the effects of aggregation prone cytosolic proteins has received less
attention. We use genetic reporters to demonstrate activation of the unfolded protein response in a transgenic Drosophila
model of Alzheimer’s disease and related tauopathies. We then use loss of function genetic reagents to support a role for
the unfolded protein response in protecting from tau neurotoxicity. Our findings suggest that the unfolded protein
response can ameliorate the toxicity of tau in vivo.
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Introduction
Tauopathies are a diverse group of neurodegenerative diseases
that are characterized by decline in cognitive and motor function,
progressive loss of neurons, and intraneuronal inclusions formed
by deposition of the microtubule binding protein tau. Tau is
normally unstructured and primarily located in axons. In
tauopathies, however, tau becomes hyperphosphorylated, fibrillar,
and aggregates in the soma and dendrites of neurons [1].
Alzheimer’s disease is the most common tauopathy. Alzheimer’s
disease is a significant public health concern, being both the most
common neurodegenerative disease and the most common cause
of dementia. In addition to intracellular tau inclusions, Alzhei-
mer’s disease brains also contain extracellular aggregates of
amyloid b (Ab) protein, derived via proteolysis from the larger
transmembrane amyloid precursor protein (APP). How Ab and
tau contribute to the pathology of Alzheimer’s disease is still
unclear; however, the appearance and anatomical distribution of
tau inclusions in Alzheimer’s disease brains correlates well with
neuronal loss, suggesting that tau plays an important role in the
progression of the disease [2]. Indeed, mutations in tau have been
found in patients with the inherited tauopathy known as
frontotemporal dementia with Parkinsonism linked to chromo-
some 17 (FTDP-17) [3–5]. These mutations establish that tau
dysfunction can cause neurodegeneration and dementia. Thus,
determining the molecular pathways that modify tau-mediated
neurotoxicity will better our understanding of the pathology of all
tauopathies, including Alzheimer’s disease, and may uncover
potential therapeutic targets.
One candidate for such a pathway is the unfolded protein
response (UPR) because the UPR appears to be upregulated in
Alzheimer’s disease [6,7]. The UPR is activated by endoplasmic
reticulum (ER) stress [8,9]. The ER is a cellular organelle with a
variety of functions, including the synthesis of lipids, carbohy-
drates, transmembrane proteins and proteins destined for secretion
or transport to other cellular organelles. Newly synthesized
proteins in the ER lumen are properly folded there, which may
include the formation of disulfide bonds. Many post-translational
modifications also occur in the ER lumen. The function of the ER
can be compromised by a variety of stressors, including inhibition
of disulfide bonding, disruption of glycosylation, depletion of ER
calcium, blocking ER to Gogi transport, increasing the ER’s
protein synthesis load, accumulation of aberrant proteins that do
not fold properly, and disruption of ER associated protein
degradation (ERAD). Many of these insults result in an increased
concentration of mis- or unfolded proteins in the ER. Upon ER
stress, sensors in the ER lumen that can detect mis- or un-folded
proteins start the intracellular signal transduction pathway called
the UPR. The first aim of the UPR is to restore ER homeostasis by
decreasing the protein load that enters the ER, stimulating the
degradation of accumulated misfolded proteins, up-regulating the
expression of genes that function in ER protein folding, and
expanding the size, and thus capacity, of the ER. However, if
homeostasis cannot be achieved and the UPR is sustained, the
UPR can also trigger cell death. The molecular mechanisms that
mediate the death of ER-stressed cells are less well understood
than those that mediate the restoration of ER homeostasis [9].
The ER stress sensors in the ER lumen activate three proteins
located in the ER membrane: inositol-requiring protein-1 (IRE-1),
activating transcription factor-6 (ATF6) and protein kinase RNA-
like ER kinase (PERK). IRE-1 is a ser/thr kinase with
endonuclease activity. When activated, it catalyzes the splicing of
Xbp1 mRNA, which causes a frame shift during Xbp1 translation.
The spliced Xbp1 protein is a transcription factor that contains a
bZIP domain as well as a potent trans-activation domain. It up-
regulates a variety of UPR-related genes involved in protein entry
to the ER, protein folding, ERAD, and protein quality control.
Activated IRE-1 also binds the adaptor protein TRAF2 to activate
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terminal kinase (JNK) pathway. ATF6 is also a bZIP transcription
factor that, when activated by ER stress, controls the expression of
many UPR genes related to ERAD, protein folding and protein
quality control in the ER. Activated PERK inhibits global protein
translation, thereby reducing ER load, by phosphorylating and
inactivating eIF2a. PERK mediated phosphorylation of eIF2a also
leads to the translation of ATF4, a transcription factor that induces
the expression of genes that function in amino acid metabolism,
the antioxidant response and apoptosis regulation [9].
Examination of postmortem material from patients with
Alzheimer’s disease has supported activation of the UPR [6,7].
Given the known role of the UPR in misfolding in the secretory
pathway, much work has focused on the role of APP, the
presenilins and the small Ab peptides derived from APP in
influencing the activity of the UPR [9]. Indeed, cell culture studies
demonstrate that Ab peptides can activate the UPR [10,11]. In
contrast, Unterberger et al. [7] found that activation of the PERK-
eIF2a pathway was not correlated with extracellular deposits of
Ab. Other studies have, in fact, suggested a relationship between
tau phosphorylation and activation of the UPR [12]. These latter
findings implicate tau in activation of the UPR in Alzheimer’s
disease, although Ab might still be playing a role either through
indirect action or soluble oligomeric species.
To address the role of tau in activating the UPR we have used
an in vivo genetic model of tauopathy in Drosophila. Expression of
human tau in Drosophila neurons recapitulates many important
aspects of human tauopathy, including age-dependent neurode-
generation [13], phosphorylation of tau [14–17], formation of
actin-rich cytoplasmic inclusions [18], oxidative stress [19], and
cell cycle-dependent apoptotic neuronal death [20]. We utilized
our Drosophila tauopathy model to explore the cause and
significance of UPR activation in tau-mediated neurodegenera-
tion. We found that the UPR is activated in a phosphorylation-
dependent fashion in tau transgenic flies, and that UPR activation
protects from tau-mediated neurotoxicity.
Results
The tauopathy model used in the current studies is based on
expression of human tau in Drosophila. In our model the bipartite
UAS/GAL4 expression system [21] is used to express human tau in
a panneural pattern with the elav-GAL4 driver. The model has been
previously described in detail [13–20]. To determine if the UPR is
activated in our tauopathy model we utilized a UAS-Xbp1-EGFP
reporter system developed by Ryoo et al. [22]. In the reporter
construct, EGFP is located after the IRE-1 splice site in Xbp1 such
that EGFP is only in frame after Xbp1 has been spliced by IRE-1.
Thus the UAS-Xbp1-EGFP transgene acts as a reporter for UPR
activation as expression of EGFP indicates that Xbp1 has been
cleaved by IRE-1. The UAS-Xbp1-EFGP transgene was first co-
expressed with human tau in Drosophila neurons using the elav-GAL4
driver. The FTDP-17 associated mutant version of tau, tau
R406W,
was used in these experiments because expression of mutant
tau
R406W induces a level of toxicity well suited for experimental
analyses [18–20]. We observed activation of the UPR reporter in
adult transgenic tau animals (Figure 1). Activation was apparent
throughout the brain, consistent with the panneural pattern of the
elav-GAL4 driver and the widespread neurodegeneration present in
tau transgenic flies [13]. To determine the cell type with reporter
activation, we double stained for elav, a marker of neurons, or repo,
a glial marker. We observed activation of the reporter in neurons
(Figure 1, upper panels), but not glia (Figure 1, lower panels). To
confirm activation of the UPR in tau transgenic flies we used an
enhancer trap P element inserted into the Hsc70-3 locus. We found
significant activation of Hsc70-3 in tau transgenic flies (27.662.6 ß-
galactosidase immunoreactive cells per brain; genotype: elav-GAL4/
Hsc70-3
G0407;UAS-tau
R406W/+) compared to controls (1.260.5 ß-
galactosidase immunoreactive cells per brain; genotype: elav-GAL4/
Hsc70-3
G0407) at 10 days of age.
To further the explore the relationship between tau expression
andUPRactivationwequantifiedthedegreeofUPRactivationflies
expressing tau transgenes that cause varying levels of neurotoxicity.
At 10 days of age, expression of human wild-type tau (tau
WT)i n
Drosophila neurons is mildly toxic, expression of the FTDP-17 linked
mutant tau (tau
R406W) is moderately toxic, and expression of a
phosphomimetic mutant tau in which 14 disease-associated SP/TP
phosphorylation sites are mutated to glutamate (tau
E14)i s
substantially more toxic [16–20]. Western blot analysis confirmed
that differences in neurotoxicity were not due to different levels of
tau expression (Figure S1), consistent with prior characterization of
Figure 1. Upregulation of unfolded protein response. Splicing of an Xbp1-EGFP reporter construct in neurons (marked by anti-elav
immunostaining, upper panels), but not glia (marked by anti-repo immunostaining, lower panels) in flies expressing tau
R40W using the panneural elav-
GAL4 driver. Scale bar is 5 mm. Flies are 10 days old.
doi:10.1371/journal.pone.0013084.g001
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ofEGFP positivenucleiwascountedin4 mmserial sectionsofentire
fly brains. UPR activation was absent in controlflies and minimal in
flies expressing only the UAS-Xbp1-EGFP reporter at 10 days of age
(Figure 2), or at one day or 30 days of age (data not shown). In
contrast, activation of the reporter was robust in flies expressing all
forms of tau (Figure 2). The degree of UPR activation correlated
very well with the degree of toxicity caused by the various forms of
tau (tau
WT=11.361.4, tau
R406W=20.762.4, tau
E14=43.062.9).
Activation of the UPR in tau transgenic flies was age dependent
(tau
R406W=6.761.1 at one day of age), consistent with our prior
characterization of age-dependent neurodegeneration in tau
transgenic flies [13]. Our findings suggest a plausible link between
tau neurotoxicity and UPR activation. Further, the substantially
increased UPR activation seen with expression of pseudopho-
sphorylated tau supports a role for tau phosphorylation upstream of
UPR activation.
To determine whether activation of the UPR influences
neurotoxicity, or is merely a marker of cellular toxicity in our
model, we determined if manipulation of the UPR modifies tau
toxicity. To decrease function of the UPR we utilized a loss of
function Xbp1 allele (Xbp1
k13803). Drosophila homozygous for the
Xbp1
k13808 allele have severely reduced Xbp1 transcript levels,
exhibit growth retardation and die before reaching the pupal stage
[22]. To assess apoptosis in adult fly brains a less severe
manipulation of Xbp1 levels was required so we examined
Drosophila Xbp1
k13808 heterozygotes. Although heterozygosity for
Xbp1
k13808 itself does not cause apoptosis, quantification of the
number of TUNEL-positive cells in 10-day-old fly brains revealed
that reducing Xbp1 function with one copy of Xbp1
k13808
significantly increased apoptosis mediated by expression of tau
(tau
R406W=24.664.2, Xbp1
k13808/+; tau
R406W=44.964.4,
p,0.05; Figure 3). Thus Xbp1 protects against the toxicity caused
by expression of tau. We confirmed these results using an RNAi
against Xbp1 (Xbp1-IR). Although expression of Xbp1-IR alone
resulted in few TUNEL positive cells (0.860.7), its co-expression
with tau more than doubled the number of TUNEL positive cells
compared to expression of tau alone (tau
R406W=24.664.2,
tau
R406W/Xbp1-IR=52.166.9, p,0.001; Figure 3). Enhance-
ment of tau toxicity by reducing Xbp1 levels did not result from
increased tau expression because Western blot analysis showed
similar levels of tau in control flies (genotype: elav-GAL4/+;UAS-
tau
R406W/+) and tau transgenic flies with reduced levels of Xbp1
(genotypes: elav-GAL4/+;UAS- tau
R406W/UAS-Xbp1-IR and elav-
GAL4/+;Xbp1
k13808/+;UAS- tau
R406W/+; Figure S2).
Since cell death is apoptotic in our model and can be decreased
by inhibiting caspase activity [23], the increased TUNEL seen in
tau transgenic fly brains when an Xbp1 loss of function allele or
Xbp1-IR is present suggests that effector caspase activity is
increased by reducing Xpb1. To further probe activation of
caspase in our system we employed a genetically encoded reporter
construct. Transgenic flies have been created that express a
caspase substrate, human poly-ADP-ribose polymerase-1 (PARP).
Human PARP is cleaved by mammalian caspase-3 and by
homologous Drosophila effector caspases. Processed PARP can then
be recognized by an antibody specific to cleaved human PARP
[24]. Human PARP was co-expressed with tau alone and with tau
in combination with Xbp1
k13808 or Xbp1-IR. An antibody to
cleaved PARP was used to detect cleavage and the number of cell
bodies with cleaved PARP was quantified. Although heterozygos-
ity for Xbp1
k13808 or expression of Xbp1-IR alone resulted in few
cells showing evidence of PARP cleavage (Xbp1
k13803/+;
PARP=1.060.5 and Xbp1-IR/PARP=4.861.8), decreasing
Xbp1 significantly increased the amount of PARP cleavage
observed with tau transgenic flies (tau
R406W, PARP=19.361.9,
Xbp1
k13803/+; tau
R406W, PARP=27.661.9, p,0.05, and Xbp1-
IR/tau
R406W, PARP=35.863.1, p,0.001; Figure 4). Of note, the
Figure 2. Quantitative analysis of Xbp1-EGFP reporter activity.
Significant activation in tau transgenic flies, with the degree of
activation correlating with the degree of toxicity of various forms of
human tau, including wild-type tau (tau
WT), FTDP-17 linked mutant
tau
R406W and the phosphomimic mutant tau
E14. No immunoreactivity
for GFP in control animals (elav-GAL4/+). *P,0.05, **P,0.01, ***
P,0.001, one-way ANOVA with Tukey test for multiple comparisons.
Flies are 10 days old.
doi:10.1371/journal.pone.0013084.g002
Figure 3. Quantitative analysis of cell death using TUNEL
staining. A significant increase in toxicity in flies with reduced levels of
Xbp1 using a loss of function allele (Xbp1
k13803/+) or by expressing RNAi
to Xpb1 (Xbp1-IR) with the panneural elav-GAL4 driver. *P,0.05,
**P,0.01, *** P,0.001, one-way ANOVA with Tukey test for multiple
comparisons. Flies are 10 days old.
doi:10.1371/journal.pone.0013084.g003
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Xbp1-EGFP reporter is similar to the number of TUNEL- and
cleaved PARP-positive neurons, consistent with a role for the UPR
in tau neurotoxicity.
We have previously demonstratedthat cell cycle activation causes
neurodegeneration in our Drosophila tauopathy model [20]. To
determine if reducing Xbp1 promotes tau-mediated neurodegen-
eration via cell cycle activation, fly brains were immunostained with
an antibody against the proliferating cell nuclear antigen (PCNA), a
marker of cell cycle activation [20], and the number of PCNA
positive foci were counted. Although aberrant PCNA expression is
minimal with Xbp1-IR alone (0.260.2% of tau
R406W), Xbp1-IR
greatly increases the aberrant PCNA expression seen in tau brains
(160.2617.7% of tau
R406W,p ,0.01; Figure 5).
Discussion
The unfolded protein response has previously been implicated
in neurodegenerative diseases. Retinitis pigmentosa is a common
form of inherited neurodegeneration often caused by mutations in
the photosensitive pigment rhodopsin. Rhodopsin is a large
transmembrane protein made at high levels in photoreceptors.
Mutations in rhodopsin cause misfolding of the protein within the
ER, and significant activation of the UPR [22]. Activation of the
UPR is most likely a protective response in retinitis pigmentosa
because activating the UPR in Drosophila models of rhodopsin
misfolding and retinal degeneration protects from photoreceptor
loss [22,25,26].
Attention has also focused on a possible role for ER stress in
Alzheimer’s disease. As mentioned above, Ab peptides can activate
the UPR [10,11]. In addition, altered presenilin function may
influence the UPR. Presenilins are multipass transmembrane
proteins that reside in the ER. In Alzheimer’s disease studies, most
attention has focused on the role of presenilins as key components
of the c-secretase complex, which is responsible for cleaving Ab
peptides from the APP precursor [27]. However, presenilins also
appear to function as channels that allow release of calcium from
the ER lumen. Mutations that predispose to familial Alzheimer’s
disease impair channel function, leading to increased ER calcium
levels [28]. Since increased calcium concentrations within the ER
can sensitize to ER stress [29], it is possible that mutations or
epigenetic factors that alter presenilin function in Alzheimer’s
disease could promote neuronal death via ER-related mechanisms.
Less attention has been given to a role for ER stress in
controlling toxicity of misfolded cytosolic proteins. Here we show
that the UPR is induced in neurons by expression of human tau in
a Drosophila model of tauopathy (Figures 1 and 2). Our findings
contrast somewhat with those of Ryoo et al. [22] who saw only
modest induction of the Xbp1-EGFP reporter in the retinas of flies
expressing the FTDP-17 associated mutant tau
R406W. In the
current study we examine tau neurotoxity in the context of aging
postmitotic neurons of the adult brain. Since evidence exist for
impairment of the ER stress response with aging [30], activation of
the UPR may be a more important response in aging postmitotic
neurons, although we have previously demonstrated good
concordance of most genetic modifiers in retinal and brain models
of human neurodegenerative diseases in Drosophila [31]. Alterna-
tively, it seems plausible that the significant ER stress caused by
misfolding of the abundant photoreceptor pigment rhodopsin
simply induces greater UPR than the soluble cytosolic protein tau.
Nonetheless, the UPR induction we observe in our model is
functionally important because we can significantly increase
neurotoxicity of tau when we reduce function of the ER stress
system by reducing levels of Xbp1 (Figures 3 and 4).
Figure 4. Increased cleaved PARP in flies with reduced levels of
Xbp1. Reduction of Xbp1 using a loss of function allele (Xbp1
k13803/+)
or RNAi to Xpb1 (Xbp1-IR) with the panneural elav-GAL4 driver.
*P,0.05, **P,0.01, *** P,0.001, one-way ANOVA with Tukey test for
multiple comparisons. Flies are 10 days old.
doi:10.1371/journal.pone.0013084.g004
Figure 5. Increased cell cycle activation in flies with reduced
levels of Xbp1. PCNA in tau transgenic flies expressing RNAi to Xpb1
(Xbp1-IR) using the panneural elav-GAL4 driver. **P,0.01, *** P,0.001,
one-way ANOVA with Tukey test for multiple comparisons. Flies are 10
days old.
doi:10.1371/journal.pone.0013084.g005
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we first determined if activation of the UPR was related to
phosphorylationof tau by using a phosphomimic version of tau with
substantially increased neurotoxicity [16–20]. Phosphorylation of
tau on proline directed sites (so called S/P and T/P sites) has been
strongly implicated in the toxicity of tau in Alzheimer’s disease [1],
and in Drosophila models of tauopathy as well [14,16–20]. We found
that pseudophosphorylation of tau at 14 S/P and T/P sites
significantly increased UPR activation, suggesting that phosphor-
ylation of tau occurs before, and promotes, UPR activation. These
findings are consistent with results from autopsy studies that have
associated activation of the UPR with phosphorylation of tau at the
AT8 epitope in Alzheimer’s disease patients [12].
We also probed the mechanism by which reduced ER stress
response leads to increased neurodegeneration. We have previ-
ously shown that tau-induced cell cycle reentry mediates neuronal
apoptosis in the fly tauopathy model [20], a result that has been
corroborated in rodent models model of tauopathy [32,33]. To
test whether reducing the ER stress response enhanced tau-
induced neurodegeneration through abnormal cell-cycle activa-
tion, we examined the levels of proliferating cell nuclear antigen
(PCNA), an S-phase cell-cycle marker abnormally upregulated in
brains of Alzheimer’s disease patients [34] and tau-expressing flies.
Since reducing levels of Xbp1 increased PCNA levels (Figure 5) as
well as markers of cell toxicity (Figures 3 and 4), reducing function
of the ER stress response most likely promotes tau neurotoxicity
through abnormal cell cycle activation.
Taken together, the results we present in the current study support
a role for the cytosolic proteintau inactivatingtheUPR. Our findings
are consistent with studies from human postmortem tissue in which
activation of the UPR was seen in two cases of tauopathies with
pathological features of progressive supranuclear palsy and cortico-
basal degeneration, conditions not associated with Ab deposition
[35]. ER stress might thus represent a point of convergence between
the dual pathologies of Ab and tau in Alzheimer’s disease. Our
genetic data suggests that activation of the UPR may play a
neuroprotective role in tauopathies because reducing Xbp1 levels
exacerbates cellular toxicity. Activation of the UPR and evaluation of
the effects on tau neurotoxicity represents an additional approach to
exploring the role of the UPR in tau neurotoxicity. Our findings are
in contrast to those obtained in a model of amyotrophic lateral
sclerosis caused by expression of a distinct cytosolic misfolded protein,
mutant superoxide dismutase (SOD). In a murine model of
amyotrophic lateral sclerosis based on expression of G93A mutant
SOD, removing Xbp1 protected from neurotoxicity, presumably
through activation of a neuroprotective autophagic response [36]. In
contrast, our findings suggest that activating, rather than inhibiting,
the ER stress response may be a potential therapeutic avenue in
Alzheimer’s disease and related tauopathies.
Materials and Methods
Fly Stocks, Genetics
All fly crosses and experiments were performed at 25uC. All flies
were analyzed at 10 days of age. The elav-GAL4 driver and Hsc70-
3
G0407 were obtained from the Bloomington Drosophila Stock
Center. The Xbp1-EGFP reporter and Xbp1
k13803 were the kindly
provided by H.D. Ryoo. The human PARP transgenic flies are
described in [24]. UAS-Xbp1-IR was obtained from the Vienna
Drosophila RNAi Center.
Sectioning, Immunostaining, and Histology
Adult flies were fixed in formalin at 10 days of age and
embedded in paraffin. Serial frontal 4 mm sections including the
entire brain were prepared. Antigen retrieval was performed by
microwaving in sodium citrate buffer, pH 6.0. Immunostaining
was performed with an avidin-biotin-peroxidase complex (ABC)
method (Vector Laboratories) or with secondary antibodies
coupled to Alexa Fluor 488 or Alexa Fluor 555. Primary
antibodies included anti-elav (Developmental Studies Hybridoma
Bank), anti-repo (Developmental Studies Hybridoma Bank), anti-
PCNA (DAKO), anti-GFP (NeuroMab), anti-PARP p85 fragment
(Promega), and anti-ß-galactosidase (Promega). For quantitative
analysis, the number of GFP-immunoreactive nuclei (Xbp1-EGFP
reporter), ß-galactosidase-immunoreactive nuclei (Hsc70-3-lacZ
reporter), cleaved PARP-positive cells, or PCNA-positive foci
were counted in the entire brain. At least six brains were analyzed
per genotype. Statistical significance was established by one-way
ANOVA with a Tukey test for multiple comparisons.
TUNEL Staining
Apoptosis was detected with the TUNEL assay with a commer-
cially available kit (TdT FragEl, Oncogene). Neurodegeneration was
quantified by counting the number of TUNEL-positive cells per brain
in consecutive frontal sections between the ellipsoid body anteriorly
and the mushroom body posteriorly. At least six brains were
examined per time point for each genotype. Statistical significance
was established by one-way ANOVA with a Tukey test for multiple
comparisons.
Western Blots
Adult Drosophila heads were homogenized in 2X Laemmli buffer
(Sigma-Aldrich). Samples were boiled for 10 minutes, briefly
centrifuged and subjected to SDS-PAGE in 10% separating gels
(Cambrex). Proteins were transferred to nitrocellulose membranes
(Bio-Rad), blocked in 2% milk in phosphate-buffered saline with
0.05% Tween-20, and immunoblotted using a phosphorylation-
independent rabbit polyclonal anti-tau antibody (1:10
6; Dako).
Ponceau S staining was used to evaluate protein loading and
transfer in all Western blots. Western blots were also reprobed
with an antibody recognizing actin (1:50,000; Sigma-Aldrich) to
illustrate equivalent protein loading.
Supporting Information
Figure S1 Western blot of total tau levels using a phosphory-
lation-independent polyclonal anti-tau antibody (Dako) reveals
equivalent levels of tau expression in flies expressing tauWT
compared to tauR406W, and slightly less expression of tauE14
compared to tauWT, despite increased toxicity in tauE14
transgenic flies (Figure 2). Control is elav-GAL4/+. The blots
were reprobed for actin as a loading control (lower panels). Flies
are 10 days old.
Found at: doi:10.1371/journal.pone.0013084.s001 (0.67 MB
TIF)
Figure S2 Western blot of total tau levels reveals equivalent
levels of tau expression in flies heterozygous for an Xbp1 loss of
function allele (Xbp1k13803) and in flies expressing RNAi to
Xpb1 (Xbp1-IR). Control is elav-GAL4/+. The blot was reprobed
for actin as a loading control (lower panel). Flies are 10 days old.
Found at: doi:10.1371/journal.pone.0013084.s002 (1.09 MB
TIF)
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